A review on iron chelators as potential therapeutic agents for the treatment of Alzheimer’s and Parkinson’s diseases

Repurposing of Copper(II)-chelating Drugs for the Treatment of Neurodegenerative Diseases

(2018) Valeria Lanza et al.   CURRENT MEDICINAL CHEMISTRY

Development of Piperazinediones as dual inhibitor for treatment of Alzheimer's disease

(2018) Devendra Kumar et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Secretase inhibitors for the treatment of Alzheimer's disease: Long road ahead

(2018) Devendra Kumar et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

The Aging of Iron Man

(2018) Azhaar Ashraf et al.   Frontiers in Aging Neuroscience

α-Synuclein aggregation modulation: an emerging approach for the treatment of Parkinson's disease

(2017) Sushil K Singh et al.   Future Medicinal Chemistry

Cortical Iron Reflects Severity of Alzheimer’s Disease

(2017) Sara van Duijn et al.   JOURNAL OF ALZHEIMERS DISEASE

The Essential Medicinal Chemistry of Curcumin

(2017) Kathryn M. Nelson et al.   JOURNAL OF MEDICINAL CHEMISTRY

Amino- and chloro-8-hydroxyquinolines and their copper complexes as proteasome inhibitors and antiproliferative agents

(2017) Valentina Oliveri et al.   Metallomics

Interactions of iron, dopamine and neuromelanin pathways in brain aging and Parkinson's disease

(2017) Fabio A. Zucca et al.   PROGRESS IN NEUROBIOLOGY

Silibinin: an old drug for hematological disorders

(2017) Hai Zou et al.   Oncotarget

The novel compound PBT434 prevents iron mediated neurodegeneration and alpha-synuclein toxicity in multiple models of Parkinson’s disease

(2017) David I. Finkelstein et al.   Acta Neuropathologica Communications

Challenges Associated with Metal Chelation Therapy in Alzheimer's Disease

(2017) Muralidhar L. Hegde et al.   JOURNAL OF ALZHEIMERS DISEASE

Brain iron chelation by deferiprone in a phase 2 randomised double-blinded placebo controlled clinical trial in Parkinson’s disease

(2017) Antonio Martin-Bastida et al.   Scientific Reports

Iron Chelation Nanoparticles with Delayed Saturation as an Effective Therapy for Parkinson Disease

(2016) Nan Wang et al.   BIOMACROMOLECULES

Deferoxamine-mediated up-regulation of HIF-1α prevents dopaminergic neuronal death via the activation of MAPK family proteins in MPTP-treated mice

(2016) Chuang Guo et al.   EXPERIMENTAL NEUROLOGY

Metal chelation, radical scavenging and inhibition of Aβ42 fibrillation by food constituents in relation to Alzheimer’s disease

(2016) Stephen Chan et al.   FOOD CHEMISTRY

Nanoparticle-mediated brain drug delivery: Overcoming blood–brain barrier to treat neurodegenerative diseases

(2016) Cláudia Saraiva et al.   JOURNAL OF CONTROLLED RELEASE

Role of iron in neurodegenerative diseases

(2016) Kai Li et al.   JOURNAL OF NEURAL TRANSMISSION

Iron neurochemistry in Alzheimer's disease and Parkinson's disease: targets for therapeutics

(2016) Abdel A. Belaidi et al.   JOURNAL OF NEUROCHEMISTRY

Iron chelation in the treatment of neurodegenerative diseases

(2016) Petr Dusek et al.   JOURNAL OF TRACE ELEMENTS IN MEDICINE AND BIOLOGY

Modulation of iron transport, metabolism and reactive oxygen status by quercetin-iron complexes in vitro

(2016) Richard D. Horniblow et al.   MOLECULAR NUTRITION & FOOD RESEARCH

Mechanisms of Neuroprotection by Quercetin: Counteracting Oxidative Stress and More

(2016) Lucio G. Costa et al.   Oxidative Medicine and Cellular Longevity

In Vitro Antioxidant versus Metal Ion Chelating Properties of Flavonoids: A Structure-Activity Investigation

(2016) Sabri Ahmed Cherrak et al.   PLoS One

Copper(II) ions affect the gating dynamics of the 20S proteasome: a molecular and in cell study

(2016) Anna Maria Santoro et al.   Scientific Reports

Inhibition of alpha-synuclein aggregation by multifunctional dopamine agonists assessed by a novel in vitro assay and an in vivo Drosophila synucleinopathy model

(2016) Deepthi Yedlapudi et al.   Scientific Reports

Clioquinol Improves Cognitive, Motor Function, and Microanatomy of the Alpha-Synuclein hA53T Transgenic Mice

(2015) David I. Finkelstein et al.   ACS Chemical Neuroscience

The novel mitochondrial iron chelator 5-((methylamino)methyl)-8-hydroxyquinoline protects against mitochondrial-induced oxidative damage and neuronal death

(2015) Natalia P. Mena et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Emerging drug targets for Aβand tau in Alzheimer's disease: a systematic review

(2015) Sophie West et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Iron is a specific cofactor for distinct oxidation- and aggregation-dependent A  toxicity mechanisms in a Drosophila model

(2015) S. Ott et al.   Disease Models & Mechanisms

Protection from neurodegeneration in the 6-hydroxydopamine (6-OHDA) model of Parkinson's with novel 1-hydroxypyridin-2-one metal chelators

(2015) David G. Workman et al.   Metallomics

Insights on the interaction of alpha-synuclein and metals in the pathophysiology of Parkinson's disease

(2015) Eleonora Carboni et al.   Metallomics

Clioquinol rescues Parkinsonism and dementia phenotypes of the tau knockout mouse

(2015) Peng Lei et al.   NEUROBIOLOGY OF DISEASE

Dangerous Leaks: Blood-Brain Barrier Woes in the Aging Hippocampus

(2015) Costantino Iadecola   NEURON

A Systems Approach to Drug Discovery in Alzheimer’s Disease

(2015) Michael Shelanski et al.   Neurotherapeutics

Potential neuroprotective properties of epigallocatechin-3-gallate (EGCG)

(2015) Neha Atulkumar Singh et al.   Nutrition Journal

Comparison of Metal Levels between Postmortem Brain and Ventricular Fluid in Alzheimer’s Disease and Nondemented Elderly Controls

(2015) Steven T. Szabo et al.   TOXICOLOGICAL SCIENCES

Ferritin levels in the cerebrospinal fluid predict Alzheimer’s disease outcomes and are regulated by APOE

(2015) Scott Ayton et al.   Nature Communications

Editorial: Metals and neurodegeneration: restoring the balance

(2015) Anthony R. White et al.   Frontiers in Aging Neuroscience

Microglial cell dysregulation in brain aging and neurodegeneration

(2015) Rommy von Bernhardi et al.   Frontiers in Aging Neuroscience

Blood–brain barrier dysfunction developed during normal aging is associated with inflammation and loss of tight junctions but not with leukocyte recruitment

(2015) Mina Elahy et al.   Immunity & Ageing

EGCG Protects against 6-OHDA-Induced Neurotoxicity in a Cell Culture Model

(2015) Dan Chen et al.   Parkinsons Disease

M30, a brain permeable multi target neurorestorative drug in post nigrostriatal dopamine neuron lesion of parkinsonism animal models

(2015) Moussa B.H. Youdim   PARKINSONISM & RELATED DISORDERS

Curcumin Treatment Improves Motor Behavior in α-Synuclein Transgenic Mice

(2015) Kateri J. Spinelli et al.   PLoS One

Multifunctional D2/D3 Agonist D-520 with High in Vivo Efficacy: Modulator of Toxicity of Alpha-Synuclein Aggregates

(2014) Gyan Modi et al.   ACS Chemical Neuroscience

Alzheimer's disease, enzyme targets and drug discovery struggles: From natural products to drug prototypes

(2014) Tiago Silva et al.   AGEING RESEARCH REVIEWS

Multitarget Drug Discovery for Alzheimer's Disease: Triazinones as BACE-1 and GSK-3β Inhibitors

(2014) Federica Prati et al.   ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

The high-affinity D2/D3 agonist D512 protects PC12 cells from 6-OHDA-induced apoptotic cell death and rescues dopaminergic neurons in the MPTP mouse model of Parkinson's disease

(2014) Mrudang Shah et al.   JOURNAL OF NEUROCHEMISTRY

The role of iron in brain ageing and neurodegenerative disorders

(2014) Roberta J Ward et al.   LANCET NEUROLOGY

Biometals and Their Therapeutic Implications in Alzheimer’s Disease

(2014) Scott Ayton et al.   Neurotherapeutics

Quercetin Inhibits Intestinal Iron Absorption and Ferroportin Transporter Expression In Vivo and In Vitro

(2014) Marija Lesjak et al.   PLoS One

The Role of Iron in Prion Disease and Other Neurodegenerative Diseases

(2014) Neena Singh   PLoS Pathogens

D-512 and D-440 as Novel Multifunctional Dopamine Agonists: Characterization of Neuroprotection Properties and Evaluation of In Vivo Efficacy in a Parkinson’s Disease Animal Model

(2013) Soumava Santra et al.   ACS Chemical Neuroscience

Targeting Chelatable Iron as a Therapeutic Modality in Parkinson's Disease

(2013) David Devos et al.   ANTIOXIDANTS & REDOX SIGNALING

Brain Iron Homeostasis: From Molecular Mechanisms To Clinical Significance and Therapeutic Opportunities

(2013) Neena Singh et al.   ANTIOXIDANTS & REDOX SIGNALING

Multifunctional iron-chelators with protective roles against neurodegenerative diseases

(2013) Andreia Nunes et al.   DALTON TRANSACTIONS

Targeting dysregulation of brain iron homeostasis in Parkinson's disease by iron chelators

(2013) Orly Weinreb et al.   FREE RADICAL BIOLOGY AND MEDICINE

Iron levels in the human brain: A post-mortem study of anatomical region differences and age-related changes

(2013) Patrícia Ramos et al.   JOURNAL OF TRACE ELEMENTS IN MEDICINE AND BIOLOGY

Development, maintenance and disruption of the blood-brain barrier

(2013) Birgit Obermeier et al.   NATURE MEDICINE

Curcumin protects against iron induced neurotoxicity in primary cortical neurons by attenuating necroptosis

(2013) Min-chao Dai et al.   NEUROSCIENCE LETTERS

Role of iron in UPS impairment model of Parkinson's disease

(2013) Weidong Le   PARKINSONISM & RELATED DISORDERS

Regional siderosis: a new challenge for iron chelation therapy

(2013) Zvi Ioav Cabantchik et al.   Frontiers in Pharmacology

Epigallocatechin-3-gallate: a useful, effective and safe clinical approach for targeted prevention and individualised treatment of neurological diseases?

(2013) Anja Mähler et al.   EPMA Journal

Multi Target Neuroprotective and Neurorestorative Anti-Parkinson and Anti-Alzheimer Drugs Ladostigil and M30 Derived from Rasagiline

(2013) Moussa B.H. Youdim   Experimental Neurobiology

Curcumin Modulates α-Synuclein Aggregation and Toxicity

(2012) Pradeep K. Singh et al.   ACS Chemical Neuroscience

Chelating Agents for Neurodegenerative Diseases

(2012) R. J. Ward et al.   CURRENT MEDICINAL CHEMISTRY

Design of iron chelators with therapeutic application

(2012) Tao Zhou et al.   DALTON TRANSACTIONS

Structure–Activity Relationship Study of N6-(2-(4-(1H-Indol-5-yl)piperazin-1-yl)ethyl)-N6-propyl-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine Analogues: Development of Highly Selective D3 Dopamine Receptor Agonists along with a Highly Potent D2/D3 Agonist and Their Pharmacological Characterization

(2012) Mark Johnson et al.   JOURNAL OF MEDICINAL CHEMISTRY

Tau deficiency induces parkinsonism with dementia by impairing APP-mediated iron export

(2012) Peng Lei et al.   NATURE MEDICINE

A Mechanistic Study of Proteasome Inhibition-Induced Iron Misregulation in Dopamine Neuron Degeneration

(2012) Xu-ping Li et al.   NEUROSIGNALS

Dopamine D2/D3 Agonists with Potent Iron Chelation, Antioxidant and Neuroprotective Properties: Potential Implication in Symptomatic and Neuroprotective Treatment of Parkinson’s Disease

(2011) Sanjib Gogoi et al.   ChemMedChem

Hydroxypyridinones as “privileged” chelating structures for the design of medicinal drugs

(2011) M. Amélia Santos et al.   COORDINATION CHEMISTRY REVIEWS

The role of metallobiology and amyloid-β peptides in Alzheimer’s disease

(2011) Blaine R. Roberts et al.   JOURNAL OF NEUROCHEMISTRY

The potential application of iron chelators for the treatment of neurodegenerative diseases

(2011) Robert C. Hider et al.   Metallomics

Multitargeting by curcumin as revealed by molecular interaction studies

(2011) Subash C. Gupta et al.   NATURAL PRODUCT REPORTS

Iron Homeostasis and the Inflammatory Response

(2010) Marianne Wessling-Resnick   Annual Review of Nutrition

Synthesis, physical–chemical characterisation and biological evaluation of novel 2-amido-3-hydroxypyridin-4(1H)-ones: Iron chelators with the potential for treating Alzheimer’s disease

(2010) Alessandra Gaeta et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Tau Pathology and Future Therapeutics

(2010) I. Gozes   Current Alzheimer Research

Discovery of 4-(4-(2-((5-Hydroxy-1,2,3,4-tetrahydronaphthalen-2-yl)(propyl)amino)ethyl)piperazin-1-yl)quinolin-8-ol and Its Analogues as Highly Potent Dopamine D2/D3 Agonists and as Iron Chelator: In Vivo Activity Indicates Potential Application in Symptomatic and Neuroprotective Therapy for Parkinson’s Disease

(2010) Balaram Ghosh et al.   JOURNAL OF MEDICINAL CHEMISTRY

The relevance of iron in the pathogenesis of Parkinson’s disease

(2010) Jeswinder Sian-Hülsmann et al.   JOURNAL OF NEUROCHEMISTRY

Novel D3 dopamine receptor-preferring agonist D-264: Evidence of neuroprotective property in Parkinson's disease animal models induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and lactacystin

(2010) Chao Li et al.   JOURNAL OF NEUROSCIENCE RESEARCH

Metals, oxidative stress and neurodegenerative disorders

(2010) Klaudia Jomova et al.   MOLECULAR AND CELLULAR BIOCHEMISTRY

Microglia in the aging brain: relevance to neurodegeneration

(2010) Xiao-Guang Luo et al.   Molecular Neurodegeneration

Nutraceutical Antioxidants as Novel Neuroprotective Agents

(2010) Natalie A. Kelsey et al.   MOLECULES

Silibinin prevents amyloid β peptide-induced memory impairment and oxidative stress in mice

(2009) P Lu et al.   BRITISH JOURNAL OF PHARMACOLOGY

Synthetic and natural iron chelators: therapeutic potential and clinical use

(2009) Heather C Hatcher et al.   Future Medicinal Chemistry

Physiological and Pathological Role of Alpha-synuclein in Parkinson’s Disease Through Iron Mediated Oxidative Stress; The Role of a Putative Iron-responsive Element

(2009) David Olivares et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Development of (S)-N6-(2-(4-(Isoquinolin-1-yl)piperazin-1-yl)ethyl)-N6-propyl-4,5,6,7-tetrahydrobenzo[d]-thiazole-2,6-diamine and Its Analogue as a D3 Receptor Preferring Agonist: Potent in Vivo Activity in Parkinson’s Disease Animal Models

(2009) Balaram Ghosh et al.   JOURNAL OF MEDICINAL CHEMISTRY

Restoration of Nigrostriatal Dopamine Neurons in Post-MPTP Treatment by the Novel Multifunctional Brain-Permeable Iron Chelator-Monoamine Oxidase Inhibitor Drug, M30

(2009) Shunit Gal et al.   NEUROTOXICITY RESEARCH

Neuromelanin Activates Microglia and Induces Degeneration of Dopaminergic Neurons: Implications for Progression of Parkinson’s Disease

(2009) Wei Zhang et al.   NEUROTOXICITY RESEARCH

Iron chelation as a potential therapy for neurodegenerative disease

(2008) Robert C. Hider et al.   BIOCHEMICAL SOCIETY TRANSACTIONS

Single Particle Characterization of Iron-induced Pore-forming α-Synuclein Oligomers

(2008) Marcus Kostka et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Safety, efficacy, and biomarker findings of PBT2 in targeting Aβ as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial

(2008) Lars Lannfelt et al.   LANCET NEUROLOGY

Rapid Restoration of Cognition in Alzheimer's Transgenic Mice with 8-Hydroxy Quinoline Analogs Is Associated with Decreased Interstitial Aβ

(2008) Paul A. Adlard et al.   NEURON

The crucial role of metal ions in neurodegeneration: the basis for a promising therapeutic strategy

(2005) Alessandra Gaeta et al.   BRITISH JOURNAL OF PHARMACOLOGY